Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) saw a large decline in short interest in January. As of January 15th, there was short interest totaling 2,155 shares, a decline of 93.6% from the December 31st total of 33,566 shares. Based on an average daily volume of 1,441 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.4% of the shares of the company are short sold. Currently, 1.4% of the shares of the company are short sold. Based on an average daily volume of 1,441 shares, the days-to-cover ratio is presently 1.5 days.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC increased its stake in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Jane Street Group LLC owned about 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent quarter.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

THNR traded down $0.57 on Wednesday, hitting $26.12. 662 shares of the company were exchanged, compared to its average volume of 1,320. Amplify Weight Loss Drug & Treatment ETF has a fifty-two week low of $18.56 and a fifty-two week high of $27.28. The business’s fifty day moving average is $25.69 and its 200 day moving average is $24.17. The firm has a market capitalization of $3.92 million, a P/E ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The company also recently disclosed an annual dividend, which was paid on Wednesday, December 31st. Investors of record on Tuesday, December 30th were paid a dividend of $0.4132 per share. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a dividend yield of 162.0%.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.